Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based Vertex Pharmaceuticals has received the Health Canada approval for Incivek (telaprevir) tablets for the treatment of patients with chronic hepatitis C with liver disease.
Subscribe to our email newsletter
The drug has been approved for use in conjunction with two different hepatitis C drugs, pegylated-interferon and ribavirin.
The combined dosage is indicated for the patients who are new to treatment, and for people who were treated previously but who did not achieve a sustained viral response (SVR, or viral cure).
The Health Canada approval was backed by the results of Phase 3 studies which demonstrated that people who received Incivek combination treatment achieved higher rates of viral cure (sustained viral response, or SVR) compared to those who received pegylated-interferon and ribavirin alone.